You are here

Integrated Biotherapeutics, Inc.

Company Information
Address
4 Research Court, Suite 300
Rockville, MD 20850-3220
United States



Information

UEI: XNTHMSN2JJP5

# of Employees: 30


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of a Panton Valentine Leukocidin bivalent vaccine

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Staphylococcus aureus (S.aureus) is a formidable human pathogen responsible for severe infections in the hospitals and community. S. aureus produces a variety of v ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  2. Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B

    Amount: $1,159,390.00

    This Phase II SBIR project addresses the need to develop a treatment for toxic shock induced by staphylococcal Enterotoxin B (SEB), which may be disseminated as an aerosol in a biowarfare scenario. S ...

    SBIRPhase II2008Department of Defense Army
  3. Therapeutic Human Hyperimmune Polyclonal Antibodies against Staphylococcal Enterotoxin B

    Amount: $109,774.00

    Research Proposed: Determine the feasibility of developing human hyperimmune serum (HIS) against staphylococcal enterotoxin B (SEB). PROBLEM/OPPORTUNITY: Staphylococcus aureus is associated with up ...

    SBIRPhase I2007Department of Defense Army
  4. Anti-Id Vaccine for the Prevention of Endotoxemia

    Amount: $50,000.00

    The hemodynamic collapse of septic shock is the leading cause of death in critically ill patients and is the thirteenth leading cause of death overall in the United States; septic shock accounts for a ...

    SBIRPhase I1993Department of Health and Human Services
  5. THE DEVELOPMENT OF MOLECULARLY PURE ANTIBODY REAGENTS TO VARIANT STRAINS OF MEASLES VIRUS

    Amount: $49,432.00

    N/A

    SBIRPhase I1993Department of Health and Human Services
  6. ANTI-ID ANTIBODY VACCINE FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS

    Amount: $43,256.00

    RESPIRATORY SYNCYTIAL VIRUS (RSV) IS NOW RECOGNIZED AS THE LEADING CAUSE OF HOSPITALIZATION OF CHILDREN DURING THE FIRST YEAR OF LIFE AS WELL AS THE LEADING CAUSE OF PEDIATRIC NOSCOMIAL INFECTION. THE ...

    SBIRPhase I1992Department of Health and Human Services
US Flag An Official Website of the United States Government